Ertahil Sit 15/100mg Tablet is a combination oral antidiabetic medicine containing pioglitazone 15mg and sitagliptin 100mg. It is used along with diet and exercise to improve blood glucose control in adults with type 2 diabetes.

Pioglitazone belongs to the thiazolidinedione class and improves the body's sensitivity to insulin. Sitagliptin is a DPP-4 inhibitor that helps increase incretin activity, supporting insulin release when blood glucose is elevated and reducing glucagon production.

The combination may be prescribed when blood sugar is not adequately controlled with one medicine alone or when combination therapy is otherwise considered appropriate.

Uses

• Helps control blood sugar in adults with type 2 diabetes
• Used alongside a healthy diet and regular exercise
• Improves insulin sensitivity
• Supports insulin release when blood glucose is elevated
• Helps reduce excessive glucagon release
• May be used as part of combination diabetes therapy

Benefits

• Combines two diabetes medicines with complementary actions
• Helps improve overall glycemic control
• Improves the body's response to insulin
• Helps reduce elevated blood glucose levels
• Has a relatively low risk of hypoglycemia when used without insulin or insulin-releasing medicines
• Convenient combination tablet

Dosage

• Take Ertahil Sit 15/100mg exactly as prescribed by your doctor.
• It can generally be taken with or without food.
• Take the tablet at approximately the same time each day.
• Your doctor may adjust treatment according to blood glucose control, kidney function, and other medical factors.
• Do not change the dose or stop treatment without medical advice.
• Continue your prescribed diet, exercise, and blood glucose monitoring plan.

Possible Side Effects

Some people may experience:

• Headache
• Nasal congestion or sore throat
• Nausea
• Stomach discomfort
• Diarrhea
• Weight gain
• Swelling or fluid retention

Pioglitazone can cause or worsen fluid retention and heart failure in susceptible patients. Sitagliptin can rarely cause pancreatitis or serious allergic reactions. Seek medical attention for significant swelling, shortness of breath, persistent severe abdominal pain, facial or throat swelling, or difficulty breathing.

Precautions

• Inform your doctor if you have heart failure, liver disease, kidney disease, bladder cancer, or a history of pancreatitis.
• Pioglitazone can cause fluid retention and may worsen heart failure.
• Kidney function should be assessed to determine whether sitagliptin dosing needs adjustment.
• The risk of low blood sugar may increase when used with insulin or sulfonylureas.
• Inform your doctor if you develop persistent or severe abdominal pain, especially if it radiates to the back.
• Tell your doctor about all medicines, vitamins, and supplements you take.
• Ertahil Sit is not intended to replace insulin in people with type 1 diabetes.

FAQs

Q1: What is Ertahil Sit 15/100mg Tablet used for?

Ertahil Sit contains pioglitazone 15mg and sitagliptin 100mg and is used with diet and exercise to improve blood sugar control in adults with type 2 diabetes.

Q2: How does Ertahil Sit 15/100mg work?

Pioglitazone improves the body's sensitivity to insulin, while sitagliptin increases incretin activity to support insulin release and reduce glucagon when blood glucose is elevated.

Q3: Can Ertahil Sit cause low blood sugar?

The combination has a relatively low risk of hypoglycemia when used alone. The risk can increase when it is combined with insulin or sulfonylureas.

Q4: Can Ertahil Sit cause weight gain or swelling?

Yes. Pioglitazone can cause weight gain and fluid retention. Contact your doctor if you develop significant swelling, rapid weight gain, or shortness of breath.

Q5: Can people with kidney problems take Ertahil Sit?

It may be used in people with kidney impairment, but sitagliptin dosing may need adjustment depending on kidney function. Your doctor should determine the appropriate dose.

Q6: Can Ertahil Sit be used for type 1 diabetes?

No. This medicine is intended for adults with type 2 diabetes and does not replace insulin therapy for type 1 diabetes.